Pierwotny skórny chłoniak z komórek b
Rokowania, prognozy i postęp choroby

Pierwotne skórne chłoniaki z komórek B (PCBCL) to heterogenna grupa nowotworów dojrzałych limfocytów B z tropizmem do skóry, różniąca się od chłoniaków węzłowych pod względem biologii i przebiegu klinicznego. Wyróżnia się trzy główne podtypy: indolentne PCFCL i PCMZL oraz agresywny PCDLBCL-LT. Indolentne podtypy cechują się doskonałym rokowaniem, z 5-letnim wskaźnikiem przeżycia powyżej 90% (PCFCL do 95%, PCMZL do 99%), natomiast PCDLBCL-LT wykazuje gorsze rokowanie z 5-letnim przeżyciem około 50%, szczególnie w lokalizacji kończynowej (41%). Rokowanie zależy od podtypu histologicznego, lokalizacji zmian (gorsze na nodze), liczby zmian (lepsze przy pojedynczych) oraz obecności rozsiewu pozaskórnego. Opracowany indeks prognostyczny CBCL-PI klasyfikuje pacjentów w cztery grupy ryzyka, z 5-letnim przeżyciem względnym od 94% w grupie IA do 34% w grupie III, co pozwala na lepsze dostosowanie strategii leczenia i monitorowania.

  1. Pierwotny skórny chłoniak z komórek B – rokowanie (ocena przewidywanych wyników)
    1. Rokowanie w zależności od podtypu
    2. Indeks prognostyczny PCBCL
    3. Czynniki wpływające na rokowanie
    4. Nawroty choroby
    5. Monitorowanie pacjentów
    6. Rzadkie podtypy o złym rokowaniu
    7. Kolejne rozdziały

Pierwotny skórny chłoniak z komórek B – rokowanie (ocena przewidywanych wyników)

Pierwotne skórne chłoniaki z komórek B (PCBCL) stanowią heterogeniczną grupę nowotworów dojrzałych komórek B wykazujących tropizm do skóry. Biologia i przebieg kliniczny tych chłoniaków znacząco różnią się od ich odpowiedników węzłowych. Przebieg kliniczny PCBCL jest zazwyczaj bardziej indolentny, a rokowanie korzystniejsze niż w przypadku chłoniaków węzłowych, pomimo wysokiego odsetka nawrotów skórnych.1

Rokowanie w zależności od podtypu

Rokowanie w pierwotnych skórnych chłoniakach z komórek B zależy od kilku czynników, w szczególności od podtypu histologicznego oraz stadium zaawansowania.2 Wyróżnia się trzy główne typy PCBCL:

3

Indolentne podtypy PCBCL, czyli PCMZL i PCFCL, charakteryzują się doskonałym rokowaniem, z 5-letnim wskaźnikiem przeżycia przekraczającym 90% w obu przypadkach. W przeciwieństwie do nich, PCDLBCL, szczególnie typ kończynowy, ma bardziej poważne rokowanie, z 5-letnim wskaźnikiem przeżycia poniżej 60%.4

Bardziej szczegółowo, 5-letnie wskaźniki przeżycia wynoszą około 95% dla PCFCL pojedynczego lub wieloogniskowego, do 99% dla PCMZL i około 50% dla PCDLBCL-LT.56 Należy jednak zauważyć, że PCFCL zlokalizowany na nodze ma gorsze rokowanie, z 41% wskaźnikiem przeżycia w ciągu 5 lat.7

Indeks prognostyczny PCBCL

Opracowano indeks prognostyczny pierwotnego skórnego chłoniaka z komórek B (CBCL-PI), który identyfikuje niekorzystne kombinacje histologii i lokalizacji skórnej. Wyróżniono cztery grupy prognostyczne:

  • Grupa IA: histologie indolentne obejmujące dowolną lokalizację skórną
  • Grupa IB: histologia rozlanego chłoniaka z dużych komórek B obejmująca korzystne miejsca skórne (głowa/szyja, ramię)
  • Grupa II: histologia rozlanego chłoniaka z dużych komórek B obejmująca niekorzystne miejsca skórne (tułów, nogi, rozsiew) lub histologia immunoblastycznego chłoniaka z dużych komórek B obejmująca korzystne miejsca skórne
  • Grupa III: histologia immunoblastycznego chłoniaka z dużych komórek B obejmująca niekorzystne miejsca skórne

8

Skorygowane współczynniki ryzyka zgonu wynosiły odpowiednio 1,0, 1,3 (95% CI, 0,99-1,7), 2,1 (95% CI, 1,6-2,7) i 4,5 (95% CI, 2,8-7,2) dla grup od IA/B do III. Odpowiadające im 5-letnie przeżycia względne wynosiły 94%, 86%, 60% i 34%.9

Czynniki wpływające na rokowanie

Istnieje kilka kluczowych czynników, które wpływają na rokowanie w PCBCL:

  • Lokalizacja zmian: Zmiany mnogościowe na nodze mają złe rokowanie. 3-letnie przeżycie specyficzne dla choroby u pacjentów z mnogimi zmianami skórnymi wyniosło 39% w porównaniu z 77% u osób z pojedynczymi zmianami10
  • Liczba zmian: Pojedyncze zmiany mają lepsze rokowanie niż zmiany mnogie11
  • Wiek i ogólny stan zdrowia pacjenta12
  • Rozsiew pozaskórny: PCDLBCL-LT często rozprzestrzenia się do miejsc pozaskórnych, co wiąże się z gorszym rokowaniem pomimo agresywnej terapii13

Nawroty choroby

Chłoniaki skórne często nawracają po leczeniu. Zmiany mogą pojawić się w tej samej okolicy lub w nowej lokalizacji. Zazwyczaj są to te same podtypy co wcześniej, ale rzadko nawracający PCBCL może manifestować się jako choroba układowa lub inny typ chłoniaka.14

Pomimo doskonałego rokowania, pacjenci z indolentnymi PCMZL i PCFCL bardzo często doświadczają nawrotów skórnych.15 Rzadko dochodzi do transformacji chłoniaków indolentnych w typy o szybszym wzroście.16

Monitorowanie pacjentów

Ze względu na dobre rokowanie, pacjentów z indolentnymi PCMZL i PCFCL należy obserwować klinicznie co 6 miesięcy. Analizy i badania radiologiczne są uzasadnione tylko w przypadku dowodów na progresję choroby. Natomiast pacjenci z PCLBCL powinni być ściśle monitorowani (tj. co miesiąc lub kwartał).17

Ważne jest, aby regularnie przeprowadzać kontrole skóry i często odwiedzać dermatologa lub innego specjalistę w celu okresowych kontroli.18

Rzadkie podtypy o złym rokowaniu

Niektóre rzadkie podtypy PCBCL charakteryzują się szczególnie złym rokowaniem:

  • Neoplazja blastycznych plazmacytoidnych komórek dendrytycznych
  • Wewnątrznaczyniowy chłoniak z dużych komórek B

1920

Podsumowując, rokowanie w pierwotnych skórnych chłoniakach z komórek B zależy głównie od podtypu histologicznego, lokalizacji i liczby zmian. Indolentne podtypy (PCMZL i PCFCL) mają doskonałe rokowanie z 5-letnim wskaźnikiem przeżycia przekraczającym 90%, podczas gdy agresywne podtypy (PCDLBCL-LT) mają gorsze rokowanie z 5-letnim wskaźnikiem przeżycia około 50%. Indeks prognostyczny CBCL-PI może pomóc w identyfikacji pacjentów z niekorzystnym rokowaniem i może być przydatny w dostosowywaniu intensywności leczenia i harmonogramu obserwacji.

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 11.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4631235/
    Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with tropism for the skin, whose biology and clinical course differ significantly from the equivalent nodal lymphomas. […] The most indolent forms comprise the primary cutaneous marginal zone and follicle center B-cell lymphomas that despite the excellent prognosis have cutaneous recurrences very commonly. […] The most aggressive forms include the primary cutaneous large B-cell lymphomas, consisting in two major groups: the leg type, with poor prognosis, and others, the latter representing a heterogeneous group of lymphomas from which specific entities are supposed to be individualized over time, such as intravascular large B-cell lymphomas. […] The clinical course of PCBCL is generally more indolent and the prognosis is usually more favorable than that of their nodal counterparts, despite the high rate of cutaneous recurrences.
  • #2 Cutaneous B-Cell Lymphoma: Types, Diagnosis, Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22925-cutaneous-b-cell-lymphoma
    Prognosis depends on several factors, especially subtype and stage. […] The two slow-growing subtypes have a five-year survival rate of about 95%. That means 95% of people are alive five years after diagnosis. But the more aggressive subtypes have a five-year survival rate of 60%. […] Skin lymphoma often comes back after treatment. Lesions may appear in the same area or a new area. They’re usually the same subtype as before. But rarely, recurrent CBCL can show up as systemic disease or another type of lymphoma. […] It’s important to perform skin checks often and see a dermatologist or other specialist regularly for check-ups.
  • #3 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #4
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4631235/
    PCMZL and PCFCL types have an excellent prognosis, with 5 year survival rates higher than 90% in both cases, while for PCLBCL, particularly leg type, prognosis is more reserved, with 5-years survival rate lower than 60%. […] Overall survival rate in 5 years for PCMZL and PCFCL is higher than 90%. In contrast, for PCLBCL, particularly leg type, prognosis is more guarded, with a survival rate in 5 years lower than 60%. […] Given the good prognosis, patients with indolent PCMZL and PCFCL should be observed from the clinical point of view every 6 months, analysis and radiological examinations being justified only if there is evidence of disease progression, whereas patients with PCLBCL should be closely monitored (i.e., monthly or quarterly).
  • #5 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #6 Cutaneous B-Cell Lymphoma: Types, Diagnosis, Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22925-cutaneous-b-cell-lymphoma
    Prognosis depends on several factors, especially subtype and stage. […] The two slow-growing subtypes have a five-year survival rate of about 95%. That means 95% of people are alive five years after diagnosis. But the more aggressive subtypes have a five-year survival rate of 60%. […] Skin lymphoma often comes back after treatment. Lesions may appear in the same area or a new area. They’re usually the same subtype as before. But rarely, recurrent CBCL can show up as systemic disease or another type of lymphoma. […] It’s important to perform skin checks often and see a dermatologist or other specialist regularly for check-ups.
  • #7 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #8 The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry – PubMed
    https://pubmed.ncbi.nlm.nih.gov/15908651/
    Four primary CBCL prognostic index (CBCL-PI) groups were identified. Group IA included indolent histologies involving any skin site. Group IB included diffuse large B-cell histology involving favorable skin sites (head/neck, arm). Group II included diffuse large B-cell histology involving unfavorable skin sites (trunk, legs, disseminated) or immunoblastic large B-cell histology involving favorable skin sites. Group III included immunoblastic large B-cell histology involving unfavorable skin sites. The adjusted mortality hazards ratios were 1.0, 1.3 (95% CI, 0.99 to 1.7), 2.1 (95% CI, 1.6 to 2.7), and 4.5 (95% CI, 2.8 to 7.2) for groups IA/B to III, respectively. The corresponding 5-year relative survivals were 94%, 86%, 60%, and 34%. […] The CBCL-PI identifies adverse combinations of histology and skin site, helping to reconcile differences in current classification and prognostic systems for PCBCL.
  • #9 The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry – PubMed
    https://pubmed.ncbi.nlm.nih.gov/15908651/
    Four primary CBCL prognostic index (CBCL-PI) groups were identified. Group IA included indolent histologies involving any skin site. Group IB included diffuse large B-cell histology involving favorable skin sites (head/neck, arm). Group II included diffuse large B-cell histology involving unfavorable skin sites (trunk, legs, disseminated) or immunoblastic large B-cell histology involving favorable skin sites. Group III included immunoblastic large B-cell histology involving unfavorable skin sites. The adjusted mortality hazards ratios were 1.0, 1.3 (95% CI, 0.99 to 1.7), 2.1 (95% CI, 1.6 to 2.7), and 4.5 (95% CI, 2.8 to 7.2) for groups IA/B to III, respectively. The corresponding 5-year relative survivals were 94%, 86%, 60%, and 34%. […] The CBCL-PI identifies adverse combinations of histology and skin site, helping to reconcile differences in current classification and prognostic systems for PCBCL.
  • #10 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #11 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #12 Skin (cutaneous) B-cell lymphoma | Lymphoma Action
    https://lymphoma-action.org.uk/types-lymphoma-skin-lymphoma/skin-cutaneous-b-cell-lymphoma
    B-cell skin lymphoma (also called cutaneous B-cell lymphoma or CBCL) is rare. Only around 100 people are diagnosed with B-cell skin lymphoma in the UK each year. […] Your outlook (prognosis) depends on lots of factors, including your age and general health and the exact type of skin lymphoma you have. Your specialist is best placed to advise you on your outlook based on your individual circumstances. […] In general, low-grade B-cell skin lymphomas have an excellent outlook. They are often diagnosed early, grow slowly and respond well to treatment. […] Primary cutaneous diffuse large B-cell lymphoma, leg type, is a high-grade lymphoma and is more aggressive in its behaviour. It needs more intensive treatment more urgently. Most people respond to treatment but it is more likely to come back (relapse) than low-grade B-cell skin lymphoma. […] Occasionally, low-grade B-cell skin lymphomas can change (transform) into a faster-growing type, although this is very rare. Your medical team should check for this. If your lymphoma transforms, you need more intensive treatment.
  • #13 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #14 Cutaneous B-Cell Lymphoma: Types, Diagnosis, Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22925-cutaneous-b-cell-lymphoma
    Prognosis depends on several factors, especially subtype and stage. […] The two slow-growing subtypes have a five-year survival rate of about 95%. That means 95% of people are alive five years after diagnosis. But the more aggressive subtypes have a five-year survival rate of 60%. […] Skin lymphoma often comes back after treatment. Lesions may appear in the same area or a new area. They’re usually the same subtype as before. But rarely, recurrent CBCL can show up as systemic disease or another type of lymphoma. […] It’s important to perform skin checks often and see a dermatologist or other specialist regularly for check-ups.
  • #15
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4631235/
    Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with tropism for the skin, whose biology and clinical course differ significantly from the equivalent nodal lymphomas. […] The most indolent forms comprise the primary cutaneous marginal zone and follicle center B-cell lymphomas that despite the excellent prognosis have cutaneous recurrences very commonly. […] The most aggressive forms include the primary cutaneous large B-cell lymphomas, consisting in two major groups: the leg type, with poor prognosis, and others, the latter representing a heterogeneous group of lymphomas from which specific entities are supposed to be individualized over time, such as intravascular large B-cell lymphomas. […] The clinical course of PCBCL is generally more indolent and the prognosis is usually more favorable than that of their nodal counterparts, despite the high rate of cutaneous recurrences.
  • #16 Skin (cutaneous) B-cell lymphoma | Lymphoma Action
    https://lymphoma-action.org.uk/types-lymphoma-skin-lymphoma/skin-cutaneous-b-cell-lymphoma
    B-cell skin lymphoma (also called cutaneous B-cell lymphoma or CBCL) is rare. Only around 100 people are diagnosed with B-cell skin lymphoma in the UK each year. […] Your outlook (prognosis) depends on lots of factors, including your age and general health and the exact type of skin lymphoma you have. Your specialist is best placed to advise you on your outlook based on your individual circumstances. […] In general, low-grade B-cell skin lymphomas have an excellent outlook. They are often diagnosed early, grow slowly and respond well to treatment. […] Primary cutaneous diffuse large B-cell lymphoma, leg type, is a high-grade lymphoma and is more aggressive in its behaviour. It needs more intensive treatment more urgently. Most people respond to treatment but it is more likely to come back (relapse) than low-grade B-cell skin lymphoma. […] Occasionally, low-grade B-cell skin lymphomas can change (transform) into a faster-growing type, although this is very rare. Your medical team should check for this. If your lymphoma transforms, you need more intensive treatment.
  • #17
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4631235/
    PCMZL and PCFCL types have an excellent prognosis, with 5 year survival rates higher than 90% in both cases, while for PCLBCL, particularly leg type, prognosis is more reserved, with 5-years survival rate lower than 60%. […] Overall survival rate in 5 years for PCMZL and PCFCL is higher than 90%. In contrast, for PCLBCL, particularly leg type, prognosis is more guarded, with a survival rate in 5 years lower than 60%. […] Given the good prognosis, patients with indolent PCMZL and PCFCL should be observed from the clinical point of view every 6 months, analysis and radiological examinations being justified only if there is evidence of disease progression, whereas patients with PCLBCL should be closely monitored (i.e., monthly or quarterly).
  • #18 Cutaneous B-Cell Lymphoma: Types, Diagnosis, Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/22925-cutaneous-b-cell-lymphoma
    Prognosis depends on several factors, especially subtype and stage. […] The two slow-growing subtypes have a five-year survival rate of about 95%. That means 95% of people are alive five years after diagnosis. But the more aggressive subtypes have a five-year survival rate of 60%. […] Skin lymphoma often comes back after treatment. Lesions may appear in the same area or a new area. They’re usually the same subtype as before. But rarely, recurrent CBCL can show up as systemic disease or another type of lymphoma. […] It’s important to perform skin checks often and see a dermatologist or other specialist regularly for check-ups.
  • #19 Cutaneous B-cell lymphoma
    https://dermnetnz.org/topics/cutaneous-b-cell-lymphoma
    Cutaneous B-cell lymphomas are a malignant proliferation of lymphocytes of the B-cell type. […] The three main types of PCBCL are: Primary cutaneous follicle centre lymphoma (PCFCL), Primary cutaneous marginal zone B-cell lymphoma (PCMZL), and Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). […] PCDLBCL-LT has the worst prognosis, with 5-year survival 50%. […] Multiple skin lesions on the leg have a poor prognosis. […] 5-year survival rates are around 95% for solitary or multifocal PCFCL. […] PCFCL on the leg has a poorer prognosis with 41% survival rate within 5-years. […] 5-year disease-specific survival of PCMZL is up to 99%. […] It is rare for PCMZL to metastasise to extra-cutaneous sites. […] PCDLBCL-LT frequently disseminates to extracutaneous sites and has a poor prognosis in spite of aggressive therapy. […] 5-year survival rates are approximately 50%. […] 3-year disease-specific survival of patients with multiple skin lesions was 39% compared to 77% in those with single lesions. […] Blastic plasmacytoid dendritic cell neoplasm and intravascular large B-cell lymphoma have a poor prognosis.
  • #20
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4631235/
    Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with tropism for the skin, whose biology and clinical course differ significantly from the equivalent nodal lymphomas. […] The most indolent forms comprise the primary cutaneous marginal zone and follicle center B-cell lymphomas that despite the excellent prognosis have cutaneous recurrences very commonly. […] The most aggressive forms include the primary cutaneous large B-cell lymphomas, consisting in two major groups: the leg type, with poor prognosis, and others, the latter representing a heterogeneous group of lymphomas from which specific entities are supposed to be individualized over time, such as intravascular large B-cell lymphomas. […] The clinical course of PCBCL is generally more indolent and the prognosis is usually more favorable than that of their nodal counterparts, despite the high rate of cutaneous recurrences.

Zobacz więcej

chłoniak strefy brzeżnej pierwotny skórny chłoniak z komórek B nawrót skórny pierwotny skórny chłoniak z ośrodków rozmnażania rozsiew pozaskórny przeżycie względne pierwotny skórny chłoniak strefy brzeżnej wskaźnik przeżycia pierwotny skórny chłoniak rozlany z dużych komórek B rozlany chłoniak z dużych komórek B